Our data suggest the downregulation of hsa-miR-127-3p contributes to the overactivation of IFN-I signaling pathway in kidney tissues of LN patients, and hsa-miR-127-3p mimics may serve as a JAK1 alternative inhibitor in treating LN. Here, JAK1 is linked to lobular neoplasia.